Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsIdentify antibodies that bind modified states of proteins with high affinity and exquisite specificity between modified and unmodified forms to power next-gen therapeutics and diagnostics.
|
PTM-Specific Rarely found binders that recognize specific post-translational modifications (PTMs) with high precision (phosphorylation, acetylation, methylation etc.) |
No Backbone Cross-Reactivity Our stringent counter-selection strategies remove unmodified protein binders in order to guarantee ultimate specificity. |
|
Developability by Design We prioritize candidates with favorable biophysical properties, reducing downstream development risks and timelines. |
Weeks to High-Affinity Leads Go from target to a panel of validated, PTM-specific antibody candidates in as little as 10-14 weeks. |
Antibody discovery against post-translational modifications (PTMs) of proteins can be challenging. Targets with inherently low immunogenicity and high homology to the unmodified protein backbone are plagued by high rates of project failure and unmet timelines. Creative Biolabs overcomes these hurdles by integrating our vast, high-diversity premade antibody libraries with expert, PTM-focused screening strategies. The result is a faster path to high-specificity, high-affinity, and downstream-ready candidates engineered for success.
Screening Platform: Precision, Speed, and Strategy
At Creative Biolabs, our phage and yeast display platforms are finely tuned to navigate the immense diversity of our libraries, deploying stringent counter-selection protocols that systematically eliminate binders to the unmodified backbone. We directly address the core challenges of PTM antibody discovery which is high background, low affinity, and poor discrimination. We deliver reliable reagents that fuel discovery, diagnostic, and therapeutic programs with minimized off-target effects and maximum biological relevance.
Our platform's power lies in its ability to dissect complex epitopes. Anti-Epitope Antibody Discovery is a broad category of services we offer for the most challenging targets:
Premade Antibody Library based TCR-Like Antibody Discovery Service
Generating antibodies against transient peptide-MHC complexes recognized by T-cells
Premade Antibody Library based Anti-Idiotype Antibody Discovery Service
Targeting the unique variable regions of other antibodies
Our end-to-end workflow is designed to de-risk PTM antibody discovery at every stage, moving rapidly from vast library diversity to a panel of validated, specific, and developable leads.
Collaborative strategy development
Optimized PTM antigen & counter-selection reagent design
Engineered for maximum specificity from day one
Upfront mitigation of common failure points
Multi-round, high-stringency panning protocols
Aggressive depletion of unmodified backbone binders
Forced enrichment of rare, PTM-specific clones
High-throughput ELISA/BLI screening
Direct comparison: PTM vs. non-PTM target binding
Data-driven ranking by specificity ratio
Cell-based assays to validate biological relevance
Epitope binning to ensure a diverse lead panel
Prioritization of functionally active candidates
NGS-driven analysis of sequence diversity
In silico screening for developability liabilities (e.g., aggregation, isomerization)
Early de-risking before investment in IgG format
Top candidates reformatted to full IgG
Rigorous biophysical assessment: solubility, thermal stability, aggregation
Confirmation of specificity and affinity in final format
Comprehensive data package delivery
Full access to all sequences and raw data
Seamless handoff to accelerate your internal program
Our libraries are the foundation of our discovery engine, designed for broad epitope coverage and superior developability.
| Antibody Library ID | Display Technology | Library Format | Library Size |
|
HuScL-6 ☆Highly Recommended |
pIII-fusion, Phagemid Phage Display | Naïve scFv | 2.1×1011 |
| HuScL-3S | pIII-fusion, Phagemid Phage Display | Semi-synthetic scFv | >1.0×1011 |
| HuFabL-4 | pIII-fusion, Phagemid Phage Display | Naïve Fab | 1.9×1010 |
| HuFabssL-1 | pIII-fusion, Phagemid Phage Display | Naïve & synthetic Fab | 1.8×1010 |
| Phospho-Specific Lead for a Kinase Pathway Target | |||||
| Project Goal | Develop a high-affinity human monoclonal antibody targeting a specific phosphorylated residue on a Protein Kinase to enable targeted signaling research. | ||||
| The Challenge | Phospho-State Discrimination: The antibody must distinguish between the phosphorylated and non-phosphorylated versions of the same peptide sequence. | ||||
| Our Solution: Strategic Synthetic Screening |
We leveraged our Synthetic Human scFv Library to isolate rare, high-specificity clones through a multi-stage biopanning strategy: Positive Selection: Utilizing conjugated phospho-peptides to capture potential binders. In-Solution Depletion: Introducing high concentrations of free non-phospho-peptides during the binding phase. This "competitive decoy" strategy effectively eliminated clones binding to the common backbone. Stringent Washing: Applying high-stringency buffers to ensure only high-affinity phospho-specific binders remained. |
||||
| Key Outcomes & Data Validation |
|
||||
Find additional antibody discovery services tailored to your specific needs.
Synergy for PTM Targets
Our massive 1011 diversity libraries combined with stringent counter-selection protocols are engineered to isolate rare PTM-specific binders that other methods miss.
Specificity by Design
We build your project around a robust negative selection strategy from day one, ensuring candidates demonstrate clean discrimination between modified and unmodified forms early.
Accelerated PTM Timelines
Our streamlined, end-to-end platform compresses the complex hit-to-lead process for PTM targets into a matter of weeks, not months.
Radical Transparency
You get end-to-end data access, including NGS clonotype analysis, enrichment curves, and ranked specificity data, empowering confident, audit-ready decisions.
QA-Backed Rigor for Downstream Success
Reproducible biophysical panels and validated human frameworks ensure the antibodies we deliver are stable, manufacturable, and ready for the next stage.
Ready to discover the PTM-specific antibodies that will drive your next breakthrough? Our team of experts is ready to design a discovery campaign tailored to your exact scientific goals.
To help us provide the most accurate proposal, please include the following in your inquiry:
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
